IIB 

115TH CONGRESS 

2D SESSION H. R. 5353 

IN THE SENATE OF THE UNITED STATES 

JUNE 13, 2018 

Received; read twice and referred to the Committee on Health, Education, 

Labor, and Pensions 

AN ACT 

To amend the Public Health Service Act to reauthorize and 

expand a program of surveillance and education, carried 

out by the Centers for Disease Control and Prevention, 

regarding infections associated with injection drug use. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 


lotter on DSKBCFDHB2PROD with BILLS
2 

HR 5353 RFS 

1 SECTION 1. SHORT TITLE. 

2 This Act may be cited as the ‘‘Eliminating Opioid Re3 lated Infectious Diseases Act of 2018’’. 

4 SEC. 2. REAUTHORIZATION AND EXPANSION OF PROGRAM 

5 OF SURVEILLANCE AND EDUCATION RE6 GARDING INFECTIONS ASSOCIATED WITH IL7 LICIT DRUG USE AND OTHER RISK FACTORS. 

8 Section 317N of the Public Health Service Act (42 

9 U.S.C. 247b–15) is amended to read as follows: 

10 ‘‘SEC. 317N. SURVEILLANCE AND EDUCATION REGARDING 

11 INFECTIONS ASSOCIATED WITH ILLICIT 

12 DRUG USE AND OTHER RISK FACTORS. 

13 ‘‘(a) IN GENERAL.—The Secretary may (directly and 

14 through grants to public and nonprofit private entities) 

15 provide for programs for the following: 

16 ‘‘(1) To cooperate with the States and Indian 

17 tribes in implementing or maintaining a surveillance 

18 system to determine the incidence of infections com19 monly associated with illicit drug use, including in20 fections commonly associated with injection drug use 

21 such as viral hepatitis, human immunodeficiency 

22 virus, and infective endocarditis, and to assist the 

23 States in determining the prevalence of such infec24 tions, which may include the reporting of cases of 

25 such infections. 


lotter on DSKBCFDHB2PROD with BILLS
3 

HR 5353 RFS 

1 ‘‘(2) To identify, counsel, and offer testing to 

2 individuals who are at risk of infections as a result 

3 of injection drug use, receiving blood transfusions 

4 prior to July 1992, or other risk factors. 

5 ‘‘(3) To provide appropriate referrals for coun6 seling, testing, and medical treatment of individuals 

7 identified under paragraph (2) and to ensure, to the 

8 extent practicable, the provision of appropriate fol9 low-up services. 

10 ‘‘(4) To develop and disseminate public infor11 mation and education programs for the detection 

12 and control of infections described in paragraph (1), 

13 with priority given to high-risk populations as deter14 mined by the Secretary. 

15 ‘‘(5) To improve the education, training, and 

16 skills of health professionals in the detection and 

17 control of infections and the coordination of treat18 ment of addiction and infectious diseases described 

19 in paragraph (1), with priority given to substance 

20 use disorder treatment providers, pediatricians and 

21 other primary care providers, obstetrician-gyne22 cologists, infectious diseases clinicians, and HIV cli23 nicians. 

24 ‘‘(b) LABORATORY PROCEDURES.—The Secretary 

25 may (directly or through grants to public and nonprofit 


lotter on DSKBCFDHB2PROD with BILLS
4 

HR 5353 RFS 

1 private entities) carry out programs to provide for im2 provements in the quality of clinical-laboratory procedures 

3 regarding infections described in subsection (a)(1). 

4 ‘‘(c) DEFINITIONS.—In this section: 

5 ‘‘(1) The term ‘Indian tribe’ has the meaning 

6 given that term in section 4 of the Indian Self-De7 termination and Education Assistance Act. 

8 ‘‘(2) The term ‘injection drug use’ means— 

9 ‘‘(A) intravenous administration of a sub10 stance in schedule I under section 202 of the 

11 Controlled Substances Act; 

12 ‘‘(B) intravenous administration of a sub13 stance in schedule II, III, IV, or V under sec14 tion 202 of the Controlled Substances Act that 

15 has not been approved for intravenous use 

16 under— 

17 ‘‘(i) section 505 of the Federal Food, 

18 Drug and Cosmetic Act; or 

19 ‘‘(ii) section 351 of the Public Health 

20 Service Act; or 

21 ‘‘(C) intravenous administration of a sub22 stance in schedule II, III, IV, or V under sec23 tion 202 of the Controlled Substances Act that 

24 has not been prescribed to the person using the 

25 substance. 


lotter on DSKBCFDHB2PROD with BILLS
5 

HR 5353 RFS 

1 ‘‘(d) AUTHORIZATION OF APPROPRIATIONS.—For the 

2 purpose of carrying out this section, there are authorized 

3 to be appropriated $40,000,000 for each of the fiscal years 

4 2019 through 2023.’’. 

Passed the House of Representatives June 12, 2018. 

Attest: KAREN L. HAAS, 

Clerk. 


lotter on DSKBCFDHB2PROD with BILLS